First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus
- 16 March 2015
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 24 (10) , 1045-1056
Abstract
Objective: The objective of this paper is to investigate the safety, pharmacokinetics (PK) and immunogenicity of CDP7657, a PEGylated anti-CD40L antibody fragment, in healthy individuals and patients with systemic lupus erythematosus (SLE). Methods: This randomized, double-blind, single-dose, dose-escalation phase I study consisted of two parts. In part 1, 28 healthy individuals received CDP7657 IV (0.004–5 mg/kg) or placebo. In part 2, 17 patients with SLE received CDP7657 IV (5–60 mg/kg) or placebo. The CDP7657:placebo ratio was 3:1. Results: Adverse events (AEs) were reported by 76% of healthy individuals and 100% of patients with SLE treated with CDP7657; most were mild or moderate in intensity. Two healthy individuals reported serious AEs (SAEs), one of which was considered treatment related (infusion-related reaction; 5 mg/kg cohort). One patient with SLE (60 mg/kg cohort) experienced three SAEs, one of which was considered treatment related (herpes zoster infection). No thromboembolic events were reported. CPD7657 exposure increased in a dose-proportional manner. Low anti-CDP7657 antibody titres were detected in the majority of CDP7657-treated participants with no apparent impact on the PK of CDP7657. Conclusion: Single doses of CDP7657 showed predictable PK in healthy individuals and patients with SLE and were well tolerated, with no safety signals of concern. These findings support further investigation of CDP7657 as a therapy for SLE.Keywords
This publication has 19 references indexed in Scilit:
- Biological Therapy in Systemic Lupus ErythematosusInternational Journal of Rheumatology, 2012
- Treatment targets in systemic lupus erythematosus: biology and clinical perspectiveArthritis Research & Therapy, 2012
- The effect of anti‐CD40 ligand in immune thrombocytopenic purpuraBritish Journal of Haematology, 2008
- An integrated view of suppressor T cell subsets in immunoregulationJournal of Clinical Investigation, 2004
- The Role of CD40–CD154 Interactions in Autoimmunity and the Benefit of Disrupting this PathwayAutoimmunity, 2004
- Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpuraBlood, 2003
- Co‐Stimulatory Blockade in the Treatment of Murine Systemic Lupus Erythematosus (SLE)Annals of the New York Academy of Sciences, 2003
- Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Thromboembolic complications after treatment with monoclonal antibody against CD40 ligandNature Medicine, 2000
- CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis.Proceedings of the National Academy of Sciences, 1996